Clinical Trial Update: Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ribociclib-endocrine therapy versus chemotherapy as first-line treatment in visceral metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED